Exelixis, Inc. (EXEL)

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

• 2/28/2026POSITIVE
  3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade

  U.S.-based biotech firm Exelixis Inc. is poised to deliver market-beating returns over the next decade, positioning itself as a key player in the oncology pharmaceutical sector. The company specializes in developing innovative cancer therapies through a diversified approach, encompassing small molecules, antibody-drug conjugates, and other biotherapeutics. This strategic focus on advanced technological platforms and a robust pipeline indicates a strong foundation for future growth. Investors should closely monitor Exelixis, as its capacity for innovation in cancer treatment could translate into substantial stock value appreciation, making it an attractive opportunity for those seeking long-term exposure to the biotech sector.

• 2/20/2026POSITIVE
  Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026

  Exelixis Inc. is a cash-generating biotech company worth a closer look for 2026. The stock is coming off a strong year, indicating a positive trajectory and future growth potential that could appeal to investors.